Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Comvita Limited maintains a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This 1 pending office action is situated in 1 distinct art unit, indicating that the company's current legal activity is confined to a specific technical niche. This lack of distribution across multiple units suggests a focused prosecution phase.
The workload involves 1 distinct examiner, which means there is no current variation in examiner perspectives for the company. FIEBIG, RUSSELL G is the busiest examiner for this portfolio, holding 1 busiest examiner pending office action. For a patent practitioner, the fact that 1 distinct examiner is responsible for the 1 pending office action implies a centralized review process. The portfolio's current status is defined by the 1 distinct art unit and the 1 distinct examiner assigned to it. This profile indicates that the company's immediate patent goals are being evaluated in a highly concentrated examination environment.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002602 | ANTI-INFLAMMATORY COMPOSITIONS, METHODS AND USES THEREOF | FIEBIG, RUSSELL G | 56d overdue |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18002602 | ANTI-INFLAMMATORY COMPOSITIONS, METHODS AND USES THEREOF | FIEBIG, RUSSELL G | 1655 | DP | Final Rejection | 56d overdue | Pending | Dec 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial